Keynote Speakers

Annamaria Locascio, PhD

Institution: Stazione Zoologica Anton Dohrn, Department of Biology and Evolution of Marine Organisms (BEOM)
Position: Research investigator
Years in position: 2009 – present

Education: 2017-National Academic Qualification as Associate Professor in Molecular Biology. Since 2002-Research investigator at the Stazione Zoologica Anton Dohrn, Naples, Italy. 1999-2002-Post-doctoral training in the Neurobiology Laboratory, Cajal Institute, CSIC, Madrid, Spain. 1999 PhD in Molecular and Cellular Biology and Pathology, University “Federico II” of Naples.
22+ years working with tunicates as models for transgenesis

Howy Jacobs

Howy Jacobs is Professor of Molecular Biology in Tampere University, Finland (since 1996). Educated in Cambridge, Glasgow and Caltech, he has spent most of his career studying mitochondria, including mtDNA transactions, the pathophysiology and molecular mechanisms of mitochondrial disease, and the properties of alternative respiratory chain enzymes. His primary experimental model is Drosophila which he applies to study mitochondrial function and dysfunction. As well as winning a number of research awards, Howy is an active member of EMBO and was Chief Editor of EMBO Reports (2009-2014). He has undertaken numerous other tasks in scientific publication, conferencing and public communication.

Professor Ignacio Anegon

Ignacio Anegon, M.D., is founder and Director of the facility Transgenesis Rats ImmunoPhenomics (TRIP) as well as co-coordinator of Team 2 at INSERM 1064-Center for Research in Transplantation and Immunology (CRTI) in Nantes, France. He was Director of INSERM-CRTI (2009-2019). His research areas are the use of genetic engineering techniques to genome edit cells and animals as well as immune tolerance (dendritic cells, CD8+ Tregs). He has published more than 275 manuscripts. He was Editor-in-Chief of Current Gene Therapy, one of the Deputy Editors of Transplantation and is member of the Editorial Board of Transgenic Research.

Professor Martin Bergo

My group’s focus is on the biochemical and medical importance of the five enzymes that post-translationally modify CAAX proteins (e.g., K-RAS, RAC1, and prelamin A) which are involved in the pathogenesis of common and rare diseases such as cancer, inflammation, and progeria. Over the past 17 years, we have defined the role of the five enzymes; studied how their activities influence disease development; and evaluated their suitability as therapeutic targets. This work also led us into new and unexpected areas including our group’s current main focus: analyzing the role of free radicals and antioxidants in cancer progression and metastasis.

Professor Ruth Palmer

The Palmer lab aims to increase our knowledge of the signal transduction pathways regulated by ALK and their significance for tumour development in vivo. To do this we focus primarily ALK driven models in Drosophila as well as mouse. Investigation of ALK signalling requires study of the ligand-mediated activation of the vertebrate ALK receptors. We and others have identified and characterised small secreted ALKAL ligands which potently activate ALK signaling. Our latest efforts in investigating ALK-driven signaling events through use of phosphor/proteomics and proximity labelling, together with the implications of our findings in ALK-driven tumorigenesis, will be presented.